MX2020004659A - Regimen de dosificacion de edasalonexent para el tratamiento de distrofia muscular. - Google Patents
Regimen de dosificacion de edasalonexent para el tratamiento de distrofia muscular.Info
- Publication number
- MX2020004659A MX2020004659A MX2020004659A MX2020004659A MX2020004659A MX 2020004659 A MX2020004659 A MX 2020004659A MX 2020004659 A MX2020004659 A MX 2020004659A MX 2020004659 A MX2020004659 A MX 2020004659A MX 2020004659 A MX2020004659 A MX 2020004659A
- Authority
- MX
- Mexico
- Prior art keywords
- muscular dystrophy
- edasalonexent
- dosing regimen
- treating muscular
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención proporciona métodos y composiciones para el tratamiento de una distrofia muscular, por ejemplo, distrofia muscular de Duchenne (DMD), en un sujeto, con un salicilato acetilado de ácido graso, por ejemplo, edasalonexent, efectivo para alcanzar un umbral de concentración plasmática del salicilato acetilado de ácido graso en el sujeto, por ejemplo, un umbral de concentración plasmática de al menos alrededor de 20 ng/ml durante al menos 12 horas en un periodo de 24 horas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581981P | 2017-11-06 | 2017-11-06 | |
| PCT/US2018/059283 WO2019090271A1 (en) | 2017-11-06 | 2018-11-05 | Edasalonexent dosing regimen for treating muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004659A true MX2020004659A (es) | 2020-10-14 |
Family
ID=66332350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004659A MX2020004659A (es) | 2017-11-06 | 2018-11-05 | Regimen de dosificacion de edasalonexent para el tratamiento de distrofia muscular. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210023029A1 (es) |
| EP (1) | EP3706730A4 (es) |
| JP (1) | JP2021502328A (es) |
| KR (1) | KR20200084877A (es) |
| CN (1) | CN111315372A (es) |
| AU (1) | AU2018359969A1 (es) |
| BR (1) | BR112020009020A2 (es) |
| CA (1) | CA3078727A1 (es) |
| CL (1) | CL2020001180A1 (es) |
| CO (1) | CO2020006395A2 (es) |
| IL (1) | IL274375A (es) |
| MX (1) | MX2020004659A (es) |
| PH (1) | PH12020550526A1 (es) |
| RU (1) | RU2020118258A (es) |
| SG (1) | SG11202004115WA (es) |
| WO (1) | WO2019090271A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020191087A1 (en) * | 2019-03-18 | 2020-09-24 | Ptc Therapeutics, Inc. | Therapeutic combinations for use in treating a muscular dystrophy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2656903T3 (es) * | 2008-07-08 | 2018-02-28 | Catabasis Pharmaceuticals, Inc. | Salicilatos acetilados de ácidos grasos y sus usos |
| PT2519230T (pt) * | 2009-12-31 | 2019-01-18 | Marius Pharmaceuticals Llc | Modulação de solubilidade, estabilidade, absorção, metabolismo e perfil farmacocinético de fármacos lipofílicos por esteróis |
| NZ601698A (en) * | 2010-01-08 | 2015-04-24 | Catabasis Pharmaceuticals Inc | Fatty acid fumarate derivatives and their uses |
-
2018
- 2018-11-05 RU RU2020118258A patent/RU2020118258A/ru unknown
- 2018-11-05 SG SG11202004115WA patent/SG11202004115WA/en unknown
- 2018-11-05 JP JP2020520142A patent/JP2021502328A/ja active Pending
- 2018-11-05 MX MX2020004659A patent/MX2020004659A/es unknown
- 2018-11-05 BR BR112020009020-4A patent/BR112020009020A2/pt not_active Application Discontinuation
- 2018-11-05 WO PCT/US2018/059283 patent/WO2019090271A1/en active Application Filing
- 2018-11-05 AU AU2018359969A patent/AU2018359969A1/en not_active Abandoned
- 2018-11-05 CN CN201880071203.6A patent/CN111315372A/zh active Pending
- 2018-11-05 KR KR1020207015893A patent/KR20200084877A/ko unknown
- 2018-11-05 EP EP18874489.0A patent/EP3706730A4/en not_active Withdrawn
- 2018-11-05 US US16/761,783 patent/US20210023029A1/en not_active Abandoned
- 2018-11-05 CA CA3078727A patent/CA3078727A1/en not_active Abandoned
-
2020
- 2020-04-30 PH PH12020550526A patent/PH12020550526A1/en unknown
- 2020-04-30 IL IL274375A patent/IL274375A/en unknown
- 2020-05-05 CL CL2020001180A patent/CL2020001180A1/es unknown
- 2020-05-27 CO CONC2020/0006395A patent/CO2020006395A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3078727A1 (en) | 2019-05-09 |
| PH12020550526A1 (en) | 2021-05-10 |
| WO2019090271A1 (en) | 2019-05-09 |
| CO2020006395A2 (es) | 2020-06-09 |
| SG11202004115WA (en) | 2020-06-29 |
| BR112020009020A2 (pt) | 2020-10-27 |
| AU2018359969A1 (en) | 2020-05-14 |
| EP3706730A4 (en) | 2021-08-11 |
| US20210023029A1 (en) | 2021-01-28 |
| IL274375A (en) | 2020-06-30 |
| EP3706730A1 (en) | 2020-09-16 |
| JP2021502328A (ja) | 2021-01-28 |
| RU2020118258A (ru) | 2021-12-08 |
| CL2020001180A1 (es) | 2020-09-25 |
| CN111315372A (zh) | 2020-06-19 |
| KR20200084877A (ko) | 2020-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125136T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1123196T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MX2019007187A (es) | Composiciones para el cuidado bucal. | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CO2018003134A2 (es) | Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2017002031A1 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
| EA201890811A1 (ru) | Способы лечения мышечной дистрофии | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| EA201490688A1 (ru) | 2-тиопиримидиноны | |
| MX2017008277A (es) | Solucion oftalmica acuosa. | |
| EA201790442A1 (ru) | Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae | |
| EA201791174A1 (ru) | Антимикотическое соединение | |
| CO2020004034A2 (es) | Métodos para el tratamiento de distrofia muscular | |
| CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| CL2017000118A1 (es) | Métodos y composiciones para tratar desórdenes relacionados con el vih | |
| MX2019007361A (es) | Composiciones para el cuidado bucal. | |
| CO2020006395A2 (es) | Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular | |
| CO2019007531A2 (es) | 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos | |
| MX2017009313A (es) | Formulaciones intravenosas de baclofeno y metodos de tratamiento. | |
| EA202092045A1 (ru) | Лечение и предупреждение преэклампсии |